

MEDTECS INTERNATIONAL CORPORATION LIMITED
(the "**Company**")
(Incorporated in Bermuda)

MINUTES OF THE ANNUAL GENERAL MEETING OF THE COMPANY

VENUE : 600 North Bridge Road, #05-01 Parkview Square, Singapore 188778

DATE & TIME : Wednesday, 30 April 2025 at 2:00 p.m.

PRESENT : As per Attendance Sheet.

1. INTRODUCTION

Mr James Lin ("**Mr Lin**"), the Chief Financial Officer of the Company, welcomed the shareholders and all present at the Company's Annual General Meeting ("**AGM**" or "**Meeting**").

Mr Lin informed the shareholders that all motions at the Meeting would be voted by way of poll and introduced the scrutineers, DrewCorp Services Pte Ltd, and the polling agent, Boardroom Corporate & Advisory Services Pte. Ltd. ("**Polling Agent**"). Mr Lin then invited the Polling Agent to explain the procedures for the poll voting process.

A representative of the Polling Agent proceeded to take the Meeting through the procedures for the poll voting process.

2. CHAIRMAN

Mr Clement Yang Ker-Cheng, Executive Chairman of the Board of Directors (the "**Board**") ("**Mr Clement Yang**" or "**Chairman**"), took the chair of the Meeting.

3. NOTICE OF MEETING & QUORUM

The Chairman introduced the Board to the Meeting.

Having ascertained that a quorum was present, the Chairman called the Meeting to order at 2.00 p.m.

With the permission of the shareholders, the Notice of the Meeting dated 15 April 2025 was taken as read.

4. OPENING ADDRESS BY CHAIRMAN

The Chairman thanked the shareholders for their continued support. He acknowledged that 2024 was marked with both challenges and transformation, for which the Company had made changes to position itself for the future. Despite market fluctuations, the Company achieved a 3.4% growth in revenue driven by its strong OEM business line, amongst reduced demand for PPE, challenges faced in the Philippines market and the glove factory.

Looking ahead, the Chairman said that the Company was focused on venturing into new markets, streamlining its operations and leveraging on technology to enhance decision-making processes. He expressed confidence that the demand for healthcare services would continue to grow globally and generate a steadier revenue stream for the Company, driving its ongoing transformation and turning it to real growth.

The Chairman informed the Meeting that he had been appointed to act as proxy for some shareholders to vote for and against certain motions and that the shareholders had been invited to submit their questions in relation to the resolutions to be tabled for approval at the AGM in advance of the Meeting. The Company did not receive any questions from the shareholders as of 22 April 2025 at 5.00 p.m.

MEDTECS INTERNATIONAL CORPORATION LIMITED
(the "**Company**")
(Incorporated in Bermuda)

MINUTES OF THE ANNUAL GENERAL MEETING OF THE COMPANY - Page 2

The Chairman then proceeded to deal with the items of ordinary business of the Meeting.

ORDINARY BUSINESS

5. ORDINARY RESOLUTION 1: DIRECTORS' STATEMENT AND THE AUDITED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2024

The Chairman presented the first item on the agenda, which was to receive and adopt the Directors' Statement and the Audited Financial Statements of the Company for the financial year ended 31 December 2024 ("**FY2024**") together with the Auditors' report thereon ("**Audited Financial Statements**").

The Chairman invited the shareholders to raise their questions, if any, relating to the Audited Financial Statements.

The questions raised by the shareholders at the Meeting which were substantial and relevant to the resolution and the responses of the Company are annexed hereto as **Appendix 1**.

There being no further questions raised, the Chairman proposed and Mr Francisco Ramon Jr seconded the following motion:

"THAT the Directors' Statement and the Audited Financial Statements of the Company for the financial year ended 31 December 2024 and the Auditors' Report thereon be hereby received and adopted."

The Chairman proceeded to put the motion to vote by way of poll. The Chairman informed the Meeting that the poll on this motion would be conducted after all motions on the agenda were dealt with.

6. ORDINARY RESOLUTION 2: RE-ELECTION OF DR NIEH CHIEN-CHUNG

The Chairman informed the Meeting that Resolution 2 was to seek shareholders' approval for the re-election of Dr Nieh Chien-Chung as a Director of the Company, who was due to retire by rotation at the Meeting pursuant to Bye-Law 86 of the Company's Bye-Laws, and being eligible, had offered himself for re-election.

The Chairman further informed the Meeting that Dr Nieh Chien-Chung, upon re-election, would remain as an Independent Director, the Chairman of the Remuneration Committee and a member of the Audit Committee and the Nominating Committee of the Company.

The Chairman invited the shareholders to raise their questions, if any, relating to Resolution 2.

There being no questions raised which were substantial and relevant to the resolution, the Chairman proposed and Ms Wan Chien Yang seconded the following motion:

"THAT Dr Nieh Chien-Chung, who retires by rotation at this meeting pursuant to Bye Law 86 of the Company's Bye-Laws, and being eligible for re-election, be hereby re-elected as a Director of the Company."

The Chairman proceeded to put the motion to vote by way of poll. The Chairman informed the Meeting that the poll on this motion would be conducted after all motions on the agenda were dealt with.

MEDTECS INTERNATIONAL CORPORATION LIMITED
(the "**Company**")
(Incorporated in Bermuda)

MINUTES OF THE ANNUAL GENERAL MEETING OF THE COMPANY - Page 3

7. ORDINARY RESOLUTION 3: RE-ELECTION OF DIRECTOR – MS JESSIE LOW MUI CHOO

The Chairman informed the Meeting that the next item on the agenda was to seek shareholders' approval for the re-election of Ms Jessie Low Mui Choo as a Director of the Company, who was due to retire by rotation at the Meeting pursuant to Bye-Law 85(2) of the Company's Bye-Laws, and being eligible, had offered herself for re-election.

The Chairman further informed the Meeting that Ms Jessie Low Mui Choo, upon re-election, would remain as an Independent Director, the Chairman of the Audit Committee and a member of the Nominating Committee and the Remuneration Committee of the Company.

The Chairman invited the shareholders to raise their questions, if any, relating to Resolution 3.

There being no questions raised which were substantial and relevant to the resolution, the Chairman proposed and Mr Francisco Ramon Jr seconded the following motion:

"THAT Ms Jessie Low Mui Choo, who retires by rotation at this meeting pursuant to Bye-Law 85(2) of the Company's Bye-Laws, and being eligible for re-election, be hereby re-elected as Director of the Company."

The Chairman proceeded to put the motion to vote by way of poll. The Chairman informed the Meeting that the poll on this motion would be conducted after all motions on the agenda have been dealt with.

8. ORDINARY RESOLUTION 4: RE-ELECTION OF DIRECTOR – MS YUHONG ZHAO

The Chairman informed the Meeting that the next item on the agenda was to seek shareholders' approval for the re-election of Ms Yuhong Zhao as a Director of the Company, who was due to retire by rotation at the Meeting pursuant to Bye-Law 85(2) of the Company's Bye-Laws, and being eligible, had offered herself for re-election.

The Chairman further informed the Meeting that Ms Yuhong Zhao, upon re-election, would remain as an Independent Director, the Chairman of the Nominating Committee and a member of the Audit Committee and the Remuneration Committee of the Company.

The Chairman invited the shareholders to raise their questions, if any, relating to Resolution 4.

There being no questions raised which were substantial and relevant to the resolution, the Chairman proposed and Ms Wan Chien Yang seconded the following motion:

"THAT Ms Yuhong Zhao, who retires by rotation at this meeting pursuant to Bye-Law 85(2) of the Company's Bye-Laws, and being eligible for re-election, be hereby re-elected as a Director of the Company."

The Chairman proceeded to put the motion to vote by way of poll. The Chairman informed the Meeting that the poll on this motion would be conducted after all motions on the agenda have been dealt with.

9. ORDINARY RESOLUTION 5: DIRECTORS' FEES FOR THE FINANCIAL YEAR ENDING 31 DECEMBER 2025

The Chairman informed the Meeting that Resolution 5 was to seek shareholders' approval for the payment of Directors' fees of S\$284,000 for the financial year ending 31 December 2025, to be paid quarterly in arrears.

The Chairman invited the shareholders to raise their questions, if any, relating to Resolution 5.

MEDTECS INTERNATIONAL CORPORATION LIMITED
(the "**Company**")
(Incorporated in Bermuda)

MINUTES OF THE ANNUAL GENERAL MEETING OF THE COMPANY - Page 4

There being no questions raised which were substantial and relevant to the resolution and at the request of the Chairman, Mr Francisco Ramon Jr proposed, and Ms Wan Chien Yang seconded the following motion:

"THAT a sum of S\$284,000 be paid by way of fees to the Directors for the financial year ending 31 December 2025 and that such fees be paid quarterly in arrears."

The Chairman proceeded to put the motion to vote by way of poll. The Chairman informed the Meeting that the poll on this motion would be conducted after all motions on the agenda were dealt with.

10. ORDINARY RESOLUTION 6: RE-APPOINTMENT OF AUDITOR

The Chairman informed the Meeting that Resolution 6 was to seek shareholders' approval for the re-appointment of Baker Tilly TFW LLP as auditor of the Company and to authorise the Directors of the Company to fix their remuneration.

The Chairman invited the shareholders to raise their questions, if any, relating to Resolution 6.

There being no questions raised which were substantial and relevant to the resolution, the Chairman proposed and Mr Francisco Ramon Jr seconded the following motion:

"THAT Baker Tilly TFW LLP be hereby re-appointed as auditor of the Company and to hold office until the conclusion of the next Annual General Meeting at a remuneration to be determined by the Directors."

The Chairman proceeded to put the motion to vote by way of poll. The Chairman informed the Meeting that the poll on this motion would be conducted after all motions on the agenda were dealt with.

11. ANY OTHER BUSINESS

As there were no further items of ordinary business, the Chairman proceeded to deal with the items of special business.

SPECIAL BUSINESS

12. ORDINARY RESOLUTION 7: SHARE ISSUE MANDATE

The Chairman briefly explained that the first item of special business on the agenda was to seek shareholders' approval to authorise and empower the Directors to allot and issue shares in the capital of the Company and/or make or grants offers, agreements or options or otherwise issue convertible securities that may or would require shares to be issued, including but not limited to the creation and issue of warrants, debentures or other instruments convertible into shares. The full text of Resolution 7 was set out under Item 8 in the Notice of Meeting.

With the permission of the shareholders, the full text of Resolution 7 was taken as read.

The Chairman invited the shareholders to raise their questions, if any, relating to Resolution 7.

There being no questions raised which were substantial and relevant to the resolution, the Chairman proposed and Ms Wan Chien Yang seconded the following motion:

"THAT pursuant to Rule 806 of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited ("**Catalist Rules**"), authority be and is hereby given to the Directors of the Company to:

MEDTECS INTERNATIONAL CORPORATION LIMITED
(the "**Company**")
(Incorporated in Bermuda)

MINUTES OF THE ANNUAL GENERAL MEETING OF THE COMPANY - Page 5

- (i) allot and issue shares in the capital of the Company (whether by way of rights, bonus or otherwise (including shares as may be required to be issued pursuant to any Instrument (as defined below)) made or granted by the Directors while this Resolution is in force notwithstanding that the authority conferred by this Resolution may have ceased to be in force at the time of issue of such shares); and/or
- (ii) make or grant offers, agreements or options or otherwise issue convertible securities (collectively, "**Instruments**") that may or would require shares to be issued, including but not limited to the creation and issue of (as well as adjustments to) warrants, debentures or other instruments convertible into shares,

at any time and from time to time upon such terms and conditions, whether for cash or otherwise, and for such purposes and to such persons as the Directors may think fit for the benefit of the Company, provided that:

- (a) the aggregate number of shares to be issued pursuant to this Resolution (including shares to be issued in pursuance of Instruments made or granted pursuant to such authority) does not exceed one hundred per cent. (100%) of the total number of issued shares excluding subsidiary holdings (as defined in the Catalist Rules) and treasury shares of the Company (as calculated in accordance with sub-paragraph (b) below), of which the aggregate number of shares to be offered other than on a pro-rata basis to shareholders of the Company (including shares to be issued in pursuance of Instruments made or granted pursuant to such authority) does not exceed fifty per cent. (50%) of the total number of issued shares excluding subsidiary holdings (as defined in the Catalist Rules) and treasury shares of the Company (as calculated in accordance with sub-paragraph (b) below);
- (b) for the purpose of determining the aggregate number of shares that may be issued under sub-paragraph (a) above, the percentage of the total number of issued shares excluding subsidiary holdings (as defined in the Catalist Rules) and treasury shares shall be calculated based on the total number of issued shares excluding treasury shares of the Company at the time of the passing of this Resolution, after adjusting for:
 - (i) new shares arising from the conversion or exercise of any convertible securities;
 - (ii) new shares arising from exercise of share options or vesting of share awards provided the options or awards were granted in compliance with Part VIII of Chapter 8 of the Catalist Rules; and
 - (iii) any subsequent bonus issue, consolidation or subdivision of shares;

provided that adjustments in accordance with sub-paragraphs (i) and (ii) above are only to be made in respect of new shares arising from convertible securities, share options or share awards which were issued and outstanding or subsisting at the time of the passing of this Resolution;

- (c) in exercising the authority conferred by this Resolution, the Company shall comply with the provisions of the Catalist Rules for the time being in force (unless such compliance has been waived by the Singapore Exchange Securities Trading Limited ("**SGX-ST**")) and the Bye-laws for the time being of the Company; and
- (d) unless revoked or varied by the Company in general meeting, the authority conferred by this Resolution shall continue in force until the conclusion of the next AGM or the date by which the next AGM is required by law or by the Bye-Laws of the Company to be held, whichever is the earlier, except that the Directors of the Company shall be authorised to allot and issue shares pursuant to any Instrument made or granted by the Directors while this Resolution was in force notwithstanding that the authority conferred by this Resolution may have ceased to be in force at the time of issue of such shares."

MEDTECS INTERNATIONAL CORPORATION LIMITED
(the "**Company**")
(Incorporated in Bermuda)

MINUTES OF THE ANNUAL GENERAL MEETING OF THE COMPANY - Page 6

The Chairman proceeded to put the motion to vote by way of poll. The Chairman informed the Meeting that the poll on this motion would be conducted after all motions on the agenda were dealt with.

13. ORDINARY RESOLUTION 8: PROPOSED RENEWAL OF THE SHARE PURCHASE MANDATE

The Chairman then proceeded to the second item of special business on the agenda, which was to seek shareholders' approval for the proposed renewal of the Share Purchase Mandate. The full text of Resolution 8 was set out under Item 9 in the Notice of Meeting.

With the permission of the shareholders, the full text of Resolution 8 was taken as read.

The Chairman invited the shareholders to raise their questions, if any, relating to Resolution 8.

There being no questions raised which were substantial and relevant to the resolution, the Chairman proposed and Mr Francisco Ramon Jr seconded the following motion:

"THAT:

- (a) for the purposes of the Companies Act 1981 of Bermuda ("**Bermuda Companies Act**") and otherwise in accordance with the rules and regulations of the SGX-ST, the exercise by the Directors of the Company of all the powers of the Company to purchase or otherwise acquire issued ordinary shares in the capital of the Company (the "**Shares**") not exceeding in aggregate the Maximum Percentage (as hereafter defined), at such price(s) as may be determined by the Directors from time to time up to the Maximum Price (as hereafter defined), whether by way of:
 - (i) on-market purchases through the SGX-ST's trading system, or as the case may be, on any other stock exchange on which the Shares may for the time being be listed and quoted, through one or more duly licensed stockbrokers appointed by the Company for the purpose ("**Market Purchases**"); and/or
 - (ii) off-market purchases in accordance with an equal access scheme as defined in Section 76C of the Companies Act 1967 of Singapore ("**Off-Market Purchases**"),and otherwise in accordance with all other laws and regulations and rules of the SGX-ST as may for the time being be applicable, be and is hereby authorised and approved generally and unconditionally (the "**Share Purchase Mandate**");
- (b) the authority conferred on the Directors of the Company pursuant to the Share Purchase Mandate to purchase and/or acquire Shares may be exercised by the Directors of the Company at any time and from time to time during the period commencing from the date of the passing of this Resolution and expiring on the earliest of:
 - (i) the date on which the next annual general meeting of the Company is held or required to be held (whereupon it will lapse, unless renewed at such AGM);
 - (ii) the date on which the authority conferred by the Share Purchase Mandate is revoked or varied by the Company at a general meeting (if so varied or revoked prior to the next AGM);
 - (iii) the date on which purchases and/or acquisitions of Shares by the Company pursuant to the Share Purchase Mandate are carried out to the full extent mandated; or

MEDTECS INTERNATIONAL CORPORATION LIMITED
(the "**Company**")
(Incorporated in Bermuda)

MINUTES OF THE ANNUAL GENERAL MEETING OF THE COMPANY - Page 7

- (iv) the date falling 12 months from the date of the AGM; and
- (c) the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including executing such documents as may be required) as they may consider expedient or necessary to give effect to the transactions contemplated by this Resolution.

In this Resolution:

"Average Closing Price" means:

- (i) in the case of a Market Purchase, the average of the Closing Market Prices (as defined below) of a Share over the last five (5) Market Days on which the Shares are transacted on the SGX-ST or, as the case may be, such securities exchange on which the Shares are listed or quoted, immediately preceding the date of the Market Purchase by the Company; or
- (ii) in the case of an Off-Market Purchase, the average of the Closing Market Prices (as defined below) of a Share over the last five (5) Market Days on which the Shares are transacted on the SGX-ST or, as the case may be, such securities exchange on which the Shares are listed or quoted, immediately preceding the date of the making of the offer pursuant to the Off-Market Purchase,

and deemed to be adjusted, in accordance with the Catalist Rules, for any corporate action that occurs during such five (5) Market Day period and the day of the Market Purchase or, as the case may be, the date of the making of the offer pursuant to the Off-Market Purchase;

"Closing Market Price" means the last dealt price for a Share transacted through the SGX-ST's trading system as shown in any publication of the SGX-ST or other sources;

"date of the making of the offer" means the date on which the Company announces its intention to make an offer for the purchase or acquisition of Shares from Shareholders, stating therein the purchase price (which shall not be more than the Maximum Price calculated on the foregoing basis) for each Share and the relevant terms of the equal access scheme for effecting the Off-Market Purchase;

"Market Day" means a day on which the SGX-ST is open for trading in securities;

"Maximum Percentage" means that number of issued Shares representing 10% of the issued Shares as at the date of the passing of this Resolution, unless the Company has, at any time during the Relevant Period, effected a reduction of the share capital of the Company in accordance with the applicable provisions of the Bermuda Companies Act, in which event the total number of issued Shares of the Company shall be taken to be the total number of issued Shares as altered by the capital reduction. Any Shares which are held as treasury shares and any subsidiary holdings will be disregarded for purposes of computing the 10% limit;

"Maximum Price" in relation to a Share to be purchased or acquired, means the purchase price (excluding related or ancillary expenses in respect of the purchase or acquisition such as brokerage, commission, applicable goods and services tax, stamp duties and clearance fees and other related expenses (where applicable)) to be paid for a Share will be determined by the Directors, provided that such purchase price must not exceed:

- (i) in the case of a Market Purchase, 105% of the Average Closing Price of the Shares; and
- (ii) in the case of an Off-Market Purchase pursuant to an equal access scheme, 120% of the Average Closing Price of the Shares; and

MEDTECS INTERNATIONAL CORPORATION LIMITED
(the "**Company**")
(Incorporated in Bermuda)

MINUTES OF THE ANNUAL GENERAL MEETING OF THE COMPANY - Page 8

"**Relevant Period**" means the period commencing from the date on which the last AGM was held and expiring on the date the next AGM is held or is required by law to be held, whichever is the earlier, after the date of this Resolution."

The Chairman proceeded to put the motion to vote by way of poll. The Chairman informed the Meeting that the poll on this motion would be conducted after all motions on the agenda were dealt with.

As all the businesses of the Meeting were dealt with, the Chairman called for the conduct of the poll on the above motions.

Following submission of the Poll Voting Slips from the shareholders to the Polling Agent, the Chairman announced that the voting was closed and requested that the Meeting be adjourned to allow time for counting of the votes by the Scrutineers. The Meeting was adjourned at 3:16 p.m.

The Meeting resumed at 3:48 p.m. after all the votes were counted and checked. The Chairman announced the results of the poll as follows:

Resolution 1 – Adoption of the Directors' Statement and the Audited Financial Statements for the financial year ended 31 December 2024

Those in favour : 265,272,083 votes (100.00%)
Those against : 2,700 votes (0.00%)

As the requisite approval by a majority of the shareholders present in persons or by proxies has been obtained at the Meeting, the Chairman declared Resolution 1 duly carried as an Ordinary Resolution.

Resolution 2 – Re-election of Dr Nieh Chien-Chung, a Director retiring by rotation pursuant to Bye-Law 86 of the Company's Bye-Laws

Those in favour : 265,169,083 votes (99.96%)
Those against : 105,700 votes (0.04%)

As the requisite approval by a majority of the shareholders present in persons or by proxies has been obtained at the Meeting, the Chairman declared Resolution 2 duly carried as an Ordinary Resolution.

Resolution 3 – Re-election of Ms Jessie Low Mui Choo, a Director retiring by rotation pursuant to Bye-Law 85(2) of the Company's Bye-Laws

Those in favour : 264,869,083 votes (99.96%)
Those against : 105,700 votes (0.04%)

As the requisite approval by a majority of the shareholders present in persons or by proxies has been obtained at the Meeting, the Chairman declared Resolution 3 duly carried as an Ordinary Resolution.

Resolution 4 – Re-election of Ms Yuhong Zhao, a Director retiring by rotation pursuant to Bye-Law 85(2) of the Company's Bye-Laws

Those in favour : 264,869,083 votes (99.96%)
Those against : 105,700 votes (0.04%)

As the requisite approval by a majority of the shareholders present in persons or by proxies has been obtained at the Meeting, the Chairman declared Resolution 4 duly carried as an Ordinary Resolution.

Resolution 5 – Approval of Directors' fees of S\$284,000 for the financial year ending 31 December 2025, to be paid quarterly in arrears

Those in favour : 207,002,600 votes (99.75%)
Those against : 523,700 votes (0.25%)

MEDTECS INTERNATIONAL CORPORATION LIMITED
(the "**Company**")
(Incorporated in Bermuda)

MINUTES OF THE ANNUAL GENERAL MEETING OF THE COMPANY - Page 9

As the requisite approval by a majority of the shareholders present in persons or by proxies has been obtained at the Meeting, the Chairman declared Resolution 5 duly carried as an Ordinary Resolution.

Resolution 6 – Re-appointment of Baker Tilly TFW LLP as auditor of the Company and to authorise the Directors of the Company to fix their remuneration.

Those in favour : 265,180,083 votes (99.96%)
Those against : 94,700 votes (0.04%)

As the requisite approval by a majority of the shareholders present in persons or by proxies has been obtained at the Meeting, the Chairman declared Resolution 6 duly carried as an Ordinary Resolution.

Resolution 7 – Ordinary Resolution giving authority for Directors to allot and issue shares.

Those in favour : 264,490,083 votes (99.70%)
Those against : 784,700 votes (0.30%)

As the requisite approval by a majority of the shareholders present in persons or by proxies has been obtained at the Meeting, the Chairman declared Resolution 7 duly carried as an Ordinary Resolution.

Resolution 8 – Ordinary Resolution giving authority for Directors for the renewal of the share purchase mandate.

Those in favour : 265,272,783 votes (100.00%)
Those against : 2,000 votes (0.00%)

As the requisite approval by a majority of the shareholders present in persons or by proxies has been obtained at the Meeting, the Chairman declared Resolution 8 duly carried as an Ordinary Resolution.

14. TERMINATION

There being no further business, the Chairman declared the Meeting was concluded and closed at 3:52 p.m. and thanked everyone for their attendance.

CONFIRMED AS A TRUE RECORD OF PROCEEDINGS HELD

CLEMENT YANG KER-CHENG
CHAIRMAN

MEDTECS INTERNATIONAL CORPORATION LIMITED
(the "**Company**")
(Incorporated in Bermuda)

MINUTES OF THE ANNUAL GENERAL MEETING OF THE COMPANY - Page 10

Appendix 1

The following substantial questions were raised by shareholders and addressed by the Company at the Meeting.

Question 1

Please provide more information on the winding up of Resilient Medical Pte. Ltd. ("**RMPL**").

Response

In the prior financial years, the Company had extended interest-bearing, repayable-on-demand advances to its subsidiary, RMPL, to fund the construction of a manufacturing facility for disposable nitrile gloves.

On 3 December 2024, the Company issued a statutory demand to RMPL for repayment of the advances. However, RMPL failed to make payment within the required period, leading to the Company to file a winding-up application against RMPL under Section 125(1)(e) of the IRDA with the Court on 27 December 2024 and subsequently, a liquidator was appointed on 17 January 2025.

In the Audited Financial Statements, the Group (i) deconsolidated RMPL and its subsidiaries; and (ii) recognised US\$27,050,000 due from RMPL and its subsidiaries. The Group then declassified said amount from due from subsidiaries to other current assets, which comprised advances made by the Group and the Company to RMPL for the funding of its construction activities.

The Company will continue to update the shareholders on the winding up of RMPL as more information becomes available.

Question 2

I refer to page 135 of the Annual Report. In 2024, the Company had made allowances for (i) a write down of US\$7,280,000 for inventory; (ii) Expected Credit Losses ("**ECL**") of US\$12,074,000 on receivables; and (iii) impairment loss of US\$138,000 on property, plant and equipment. Is the Company expecting more of such receivables?

Response

The allowances were made based on the management's assessment of the collectability of the receivables, pursuant to a more conservative approach. The allowance for inventory write-down was due to a one-time provision for inventory losses for high and slow-moving PPE inventories post-COVID-19. The allowance for ECL on receivables was primarily related to receivables from the Company's investment in the glove factory through RMPL, for which restructuring processes are already underway for the Company to regain direct control over RMKH Glove (Cambodia) Co., Ltd. and to enable a full recovery of the receivables, in parallel with the winding up of RMPL.

Question 3

Please share the impact to the Company's performance in light of COVID-19 and recent geopolitical events, particularly the US tariffs.

Response

The Company had accounted for the receivables and inventories post-COVID-19 and is in a better position moving towards more stable and improved financial performance. Operationally, the Company is seeing normalised order flows and improving fundamentals across its core businesses.

Given that the Group's current revenue exposure to the US market is approximately 5% and that the Group has a diversified customer base across Europe, Africa and ASEAN, the impact from the US tariffs

MEDTECS INTERNATIONAL CORPORATION LIMITED
(the "**Company**")
(Incorporated in Bermuda)

MINUTES OF THE ANNUAL GENERAL MEETING OF THE COMPANY - Page 11

remains manageable. Meanwhile, the Company may leverage on its production sites in the Philippines and look out for potential opportunities of new orders that may be redirected from China.

*This document has been prepared by the Company and its contents have been reviewed by the Company's sponsor, R & T Corporate Services Pte. Ltd. ("**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("**Exchange**").*

This document has not been examined or approved by the Exchange. The Exchange assumes no responsibility for the contents of this document including the correctness of any of the statements or opinions made or reports contained in this document.

The contact persons for the Sponsor are Ms Evelyn Wee (Telephone Number: +65 6232 0724) and Mr. Howard Cheam Heng Haw (Telephone Number: +65 6232 0685), R & T Corporate Services Pte. Ltd., at 9 Straits View, Marina One West Tower, #06-07 Singapore 018937.